secwatch.observer — SEC 8-K summary
======================================

Issuer:     Intellia Therapeutics, Inc. (NTLA)
CIK:        0001652130
Form:       8-K
Filed at:   2026-04-27T23:59:59+00:00
Accession:  0001193125-26-179401
Event type: other_material
Sentiment:  positive
Materiality: 0.95
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Intellia announces positive Phase 3 HAELO results: 87% attack reduction, 62% attack-free; starts BLA for lonvo-z
--------------------------------------------------------------------------------

- Single dose of lonvo-z reduced HAE attacks by 87% vs placebo (mean monthly rate 0.26 vs 2.10, p<0.0001) over 6 months.
- 62% of lonvo-z patients were entirely attack-free and therapy-free vs 11% on placebo (p<0.0001); all key secondary endpoints met.
- No serious adverse events; all TEAEs mild/moderate; most common: infusion-related reactions, headache, fatigue.
- Rolling BLA submission to FDA initiated; potential U.S. launch in first half of 2027 if approved.
- Median follow-up 7.5 months; all lonvo-z patients remained long-term prophylaxis-free as of Feb 10, 2026 cutoff.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1652130/000119312526179401/0001193125-26-179401-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1652130/000119312526179401/d138980d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-179401

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer